Abstract

  In December 2019, another coronavirus, named SARS-CoV-2, has risen up out of China causing pneumonia episodes first in the Wuhan locale and have now spread overall in view of its plausible high transmission productivity. Because of the absence of productive and explicit medicines and the need to contain the pestilence, medicate repurposing has all the earmarks of being the best instrument to discover remedial arrangement. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have demonstrated viability to restrain coronavirus in vitro. Teicoplanin, an anti-microbial used to treat staphylococci disease, recently demonstrated adequacy to hinder the principal phase of MERS coronavirus viral cycle in human cells. This action is preserved on the SARS-Cov-2, accordingly putting teicoplanin as an expected treatment for patients with this infection.

Keywords: SARS-CoV-2; Drug Repurposing; Teicoplanin; COVID-19

References

1. Zhu N., et al. “A Novel Coronavirus from Patients with Pneumonia in China, 2019”. The New England Journal of Medicine 382 (2020): 727-733.
2. Lai C-C., et al. “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges”. International Journal of Antimicrobial Agents (2020): 105924.
3. Devaux C., et al. “New insights for antiviral effects of chloroquine against coronavirus: what to expect for COVID 19?” International Journal of Antimicrobial Agents (2020).
4. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research (2020).
5. Colson P., et al. “Chloroquine for the 2019 novel coronavirus SARSCoV-2”. International Journal of Antimicrobial Agents (2020): 105923.
6. Ko W-C., et al. “Remdesivir for SARS-CoV-2 pneumonia”. International Journal of Antimicrobial Agents (2020).
7. Zhang J., et al. “Teicoplanin potently blocks the cell entry of 2019-nCoV”. BioRxiv (2020).
8. Zhou N., et al. “Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)”. Journal of Biological Chemistry 291 (2016): 9218-9232.
9. Colson P and Raoult D. “Fighting viruses with antibiotics: an overlooked path”. International Journal of Antimicrobial Agents 48 (2016): 349-352.
10. Pan T., et al. “Use of teicoplanin anti-middle east respiratory syndrome coronavirus”. WO/2016/201692 (2015).

Citation

Citation: Anirban Adhikary., et al. “A Review on Teicoplanin Used as Alternative Drug to Treat the Novel Corona Virus (COVID – 19)". Acta Scientific Microbiology 3.10 (2020): 59-60.

Copyright

Copyright: © 2020 Anirban Adhikary., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.